As it was reported that cathepsin L-deficient NOD mice are protected from insulitis and diabetes due to the increased number of regulatory T (Treg) cells in the periphery through the defective thymic selection [10], the therapeutic application with cathepsin inhibitor may be clinically useful. This evidence concerns the gene CTSL and diabetes mellitus.